Pharmaceutical R&D Innovation a≈♦nd IP Protection -- Global Vision
-
Interpretation of Policy-Pharmaceutical Intel≥±σ>lectual Property Policies and Regulat←>♦ions under the New SituationDay one morning2019.11.14
-
Day one afternoon2019.11.14
-
Case Sharing of Inva↓§lidity, Infringement, Litiga÷λ∏tionDay two morning2019.11.15
-
Opportunities and challenges★ for generics companies ××↔under the new situationDay two afternoon2019.11.15
Interpretation of Policy-Pharmaceutical Intel★↓lectual Property Policies and Regul¶★$ ations under the New ✘ Situation
Opening and Chairman’s Welcome Address
Medical Policy Interpretation u₹→nder the Background of ∑&♦£Patent Law Amendment
------ In December 2018, The Executiδve Meeting of The State Council deliber₩§♠ated and adopted the☆πβ draft amendment to the pa<δβ tent law, which has been reviewed for the first÷±λ time by the NPC and is expected to be c♣•∞≠ompleted within this year. In parti₽★≠ cular for innovative drugs added invention ↕αpatent protection extended the ex×αceptional provisions.
The innovation of Judicial M €'♦echanism Promotes the ΩDevelopment of Pharmaceutiβ cal Intellectual Property
Networking Coffee Break
WIPO’s Patent Cooperation Treat$¥y applications: global gateway for Pharma ≠<and Biotech. (TBD)
Networking Luncheon
Pharmaceutical R&D Innovation and IP Protectiπ≠on -- Global Vision
Intellectual Property Manage§π ment Experience in Mu≈•∑ltinational Pharmaceutical Companies♠≥§π, Patent Layout Strategy, Litigation Strat±$egy
PATENT INNOVATION: PATIE§πNT VALUE FIRST
Hotspot Issues about Medicine ★≤✔Patent Litigation in China
Networking Coffee Break
Establishing The Internal Intel₽↕δ↓lectual Property System under The ₩↓New Legislative Landscape
Panel Discussion: Opportunities and Challenges of Pharmaceut"₩ical Enterprises under Patent Term Compensa&≈®tion System--- Global Vision σβ↓and Its Implications↕→★♠ for China
------- On January 4, 2019, 《Amendment to the patent law of the People&↔•#39;s Republic of China (Draft)》 was published, which me¥φ↑ntioned that "The State Coun×' cil can decide to extend the p↔©atent term for the inventio☆σ®←n patent of innovative drugs that are synchronou≤>£ sly applied for listi>λ¥$ng in China and abroad". φNew opportunities are opening up f&∞$ or new drug development in China.
------- Comparison of patent term compen®₩☆sation system between China and™φ'§ foreign countries
------- Opportunity or challeng÷×e under the new rules
Cocktail &Networking（Sponsorship Opportunities）
The end of the first day
Case Sharing of Invalidity, Infriσ∞ngement, Litigation
Opening Address
Latest Changes in European Patentλ™ Application and Review Procedu↔≤res
-------On March 12, 2019, ★γ¶₽the European Patent Office (EPO) rel←σeased the 2018 annual repor∞ σ<t, which showed that the number of patent applica©&≥tions in China increased significantly, and t<Ωhe growth in life sciences$• was the fastest, and Chinese pharmaceλ↔↔utical companies reached a peak in the layout of →Europe.The European Patent Offic✘<&✘e (EPO) has just publ©₽✔∑ished a new edition of Guidelines £±✔×for Examination. The new guid★φelines will take effect from↑×ε November 1, 2018.
Analysis of Hot Cases"≠ of Recent Patent invalidation
Europe and American Pharm&♣aceutical Patent litigati ★"on and its Enlightenment to Chinese Pharmaceu$ tical Enterprises (TBD)♥₩
------ Will Brexit change anyt₹ ₹hing for litigation?
------ Planning a Europπ>'ean/US strategy
Networking Coffee Break
Application techniques an✔ £<d protection strategies fo₹¥∏r European and American biomedical pa ★♠™tents
------ Internal review∞λ¥ procedures and application
------ Recent successful intellectual pro↕✔¶σperty strategies and possible prob™≠™₽lems
------ How can the i₹™♠ntellectual propertyλ♥± findings be effectively incorporated into the♠β patent drafting process to ensure the legitimacy>₩ of U.S. courts?
------ American vision
Panel Discussion: European, American and Japanes÷∞Ωe Medical Patent Examination Cases and ®≈ its implications for Domestic Pharmaceut≠αical Companies ------- Various countries' review process and sφγ₹tandards
------- Changes in standards ε♦σ×for creative review of patents
------- Research on the standards of repeated authorizati'>εon review
Opportunities and challe₽σ nges for generics companies ±←under the new situatγ¶★ion
Challenge Strategy and commercial value →↑of Generic Drug Patents
The Strategy of Indian Generic Drug C∏₩↔≤ompanies in R&D and×↔ Pre-PA
Networking Coffee Break
Patent game in drug dαλ&evelopment
Recent Hot Patent Infringement Cases ☆§₩>Analysis
------ With the advent of the patent cliff,≠δπα the disputes increase bet→≈$ween the primary drug companies and g≥&→λeneric drug companies
Panel Discussion:
The Strategy of Generic Drug Companies to Enterγ↕§ the European and American Markets
------- Various countries' review proce'∑ss and standards
------- Changes in standards for creat≤ε☆ive review of patents
------- Research on the standaαφrds of repeated authorization★≥→ review
Key Lee
+86 15801952437
+86 21 65650305
key@zenseegroup.com
Frank Zhang
+86 15021074081
+86 21 65650305
frank.zhang@zenseegrou✔εp.com
Ann Yang
marketing@zenseegroup.com
+86 21 65651072
Register Now
Please call the conference comm∞∏ittee at 86 21 65650305 or fill in the form. We wσ₩™ill contact you as soon as possibl★<e